ELVN logo

ELVN
Enliven Therapeutics Inc

1,299
Mkt Cap
$2.52B
Volume
3,497.00
52W High
$48.53
52W Low
$14.79
PE Ratio
-24.89
ELVN Fundamentals
Price
$41.41
Prev Close
$42.53
Open
$42.67
50D MA
$40.54
Beta
1.47
Avg. Volume
1.02M
EPS (Annual)
-$1.83
P/B
5.56
Rev/Employee
$0.00
$410.41
Loading...
Loading...
News
all
press releases
Enliven Therapeutics to Present at Upcoming Investor Conferences
Enliven Therapeutics to Present at Upcoming Investor Conferences Enliven Therapeutics to Present at Upcoming Investor Conferences PR Newswire BOULDER, Colo., May 21, 2026 BOULDER, Colo., May 21, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a...
News Placeholder
More News
News Placeholder
ELVN Stock Climbs As Guggenheim Launches Coverage With $80 Price Target Ahead Of Conference Data Unveil
Enliven said that updated positive early-stage data for its lead candidate ELVN-001 will be featured in an oral presentation at the EHA 2026 Congress in Stockholm.
News Placeholder
Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML
Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in...
News Placeholder
Why is Enliven Therapeutics (ELVN) One of the Best Performing Healthcare Stocks so Far in 2026?
Why is Enliven Therapeutics (ELVN) One of the Best Performing Healthcare Stocks so Far in 2026...
News Placeholder
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update PR Newswire...
News Placeholder
Wall Street Zen Downgrades Enliven Therapeutics (NASDAQ:ELVN) to Sell
Wall Street Zen downgraded shares of Enliven Therapeutics from a "hold" rating to a "sell" rating in a research report on Sunday...
News Placeholder
Enliven Therapeutics (NASDAQ:ELVN) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen upgraded Enliven Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday...
News Placeholder
Enliven Therapeutics (NASDAQ:ELVN) Hits New 1-Year High - Time to Buy?
Enliven Therapeutics (NASDAQ:ELVN) Reaches New 12-Month High - Should You Buy...
News Placeholder
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Short Interest Down 26.3% in March
Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) was the recipient of a large drop in short interest in the month of March. As of March 31st, there was short interest totaling 6,053,456...
News Placeholder
Enliven Therapeutics (NASDAQ:ELVN) Stock Price Down 4.2% - What's Next?
Enliven Therapeutics (NASDAQ:ELVN) Trading Down 4.2% - What's Next...
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available